| Title |
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
|
|---|---|
| Published in |
Digestive Diseases and Sciences, February 2018
|
| DOI | 10.1007/s10620-018-4971-1 |
| Pubmed ID | |
| Authors |
Mark Fleisher, Jan Marsal, Scott D. Lee, Laura E. Frado, Alyssa Parian, Burton I. Korelitz, Brian G. Feagan |
| Abstract |
Approximately 15-20% of ulcerative colitis patients and 20-40% of those with Crohn's disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action. This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action. We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy. Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn's disease. These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 121 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 121 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 17 | 14% |
| Researcher | 15 | 12% |
| Other | 11 | 9% |
| Student > Master | 11 | 9% |
| Student > Bachelor | 8 | 7% |
| Other | 28 | 23% |
| Unknown | 31 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 61 | 50% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Nursing and Health Professions | 5 | 4% |
| Immunology and Microbiology | 3 | 2% |
| Arts and Humanities | 2 | 2% |
| Other | 8 | 7% |
| Unknown | 37 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2018.
All research outputs
#15,921,972
of 25,195,876 outputs
Outputs from Digestive Diseases and Sciences
#2,967
of 4,606 outputs
Outputs of similar age
#194,709
of 336,181 outputs
Outputs of similar age from Digestive Diseases and Sciences
#45
of 83 outputs
Altmetric has tracked 25,195,876 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,606 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,181 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.